ASPI · ASP Isotopes Inc. Common Stock

Summary

ASP Isotopes Inc. filed an 8-K/A furnishing Exhibit 99.1 with risk factors related to Renergen's Virginia Gas Project Phase 2 expansion, Exhibit 99.2 with Renergen's reviewed interim consolidated financial statements for the six months ended August 31, 2025 showing revenue of R29,093 thousand and net loss of R139,654 thousand, and Exhibit 99.3 with unaudited pro forma condensed combined financial statements for the acquisition of Renergen completed January 6, 2025.